Remlife Global Pte Ltd., a Singapore-based subsidiary of Remedium Lifecare Ltd., has announced a forward-looking partnership with JiyaYu Lifesciences Pte Ltd., a green chemistry technology platform company. This collaboration is focused on replacing animal-origin raw materials in the manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates through proprietary fermentation and biocatalyst-based alternatives.

As part of the partnership, JiyaYu will license out fully developed and scalable technologies to Remlife Global on an exclusive basis. These technologies are designed to replace traditional animal-derived steps with sustainable, cost-effective, and regulatory-compliant bioprocesses. Remlife Global will scale up and commercialise these technologies at one or more GMP-compliant contract manufacturing sites across India, Singapore, Malta, Ireland, Belgium, and Italy.

JiyaYu Lifesciences has in turn partnered with a UK-based R&D technology platform specialising in the development of fermentation and biocatalyst-based alternatives to animal-origin pharmaceutical inputs. Through this collaboration, JiyaYu gains access to cutting-edge innovations that it will transfer to Remlife Global as fully scalable technologies.

Each technology will be supported by detailed process dossiers and full technology transfer documents, enabling Remlife Global to implement, validate, and scale up the processes at approved GMP manufacturing sites.

These solutions will support Remlife Global's vision of eliminating dependence on vulnerable and ethically complex supply chains, while capturing new commercial opportunities in global regulated markets.

Commenting on the development, Adarsh Munjal, Managing Director, Remedium Lifecare said, “Our collaboration with JiyaYu Lifesciences is a transformative move toward building a more ethical, resilient, and sustainable pharmaceutical supply chain.”

Remlife Global's strategic direction is anchored in the belief that the future of pharmaceuticals lies in sustainable, animal-free production. Key reasons for this shift include ethical and ESG alignment, as modern pharmaceutical companies face increasing pressure to eliminate animal-based components from their supply chains.

Fermentation and biocatalyst-based systems also offer enhanced safety and quality control, providing greater consistency and reducing the risk of contamination from animal-borne pathogens. Additionally, these alternatives improve supply chain resilience by mitigating risks associated with diseases, regulatory changes, and geopolitical instability that can disrupt the availability of animal-derived inputs, the company stated.

It further added that from an environmental standpoint, traditional animal-based raw materials are associated with high greenhouse gas emissions, extensive land use, and significant water consumption. “Lastly, industry momentum is building, with leading global pharmaceutical firms increasingly incorporating bio-based and cruelty-free technologies into their development pipelines,” it said.